• Citer

Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency.

par Surquin, Murielle ;Tielemans, Christian ;Nortier, Joëlle ;Jadoul, Michel;Peeters, Patrick;Ryba, Miroslav;Roznovsky, Ludek;Doman, József;Barthelemy, Xavier;Crasta, Priya Diana;Messier, Marc;Houard, Sophie
Référence Human vaccines, 7, 9, page (913-918)
Publication Publié, 2011-09

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Three doses of the investigational AS02(v)-adjuvanted hepatitis B virus (HBV) vaccine HB-AS02 have been shown to induce more rapid seroprotection and higher anti-HBs antibody concentrations in patients with renal insufficiency than four doses of FENDrix™ (HB-AS04), an adjuvanted HBV vaccine licensed in Europe for use in this population. This study evaluated persistence of immune response up to 36 months after primary vaccination.